Cancer Control (93.399)
Cancer Control (Assistance Listing 93.399) is run by the National Institutes of Health, part of the Department of Health and Human Services. It awarded $814 million in 113 grants from fiscal 2021 to 2025, about $7.2 million per award on average. 52 funding opportunities are open or forecast now.
The typical award was $4.2 million. Half of the 113 awards fell between $1.8 million and $7.3 million, and they ranged from $61,600 to $87.9 million.
- Awarded, FY 2021 to 2025$814 million
- Grant awards113
- Typical award$4.2 million
- Awarded in FY 2025$172 million
- Size rank279 of 1824
- Type of assistanceProject grants, project grants (cooperative agreements)
Key findings
- Annual funding rose from $145 million in fiscal 2021 to $172 million in fiscal 2025.
- It is the 279th largest of 1,824 federal grant programs by five-year awards.
- The 20 largest recipients received 61% of the money.
- Awards went to recipients in 37 states and territories.
What the program funds
To reduce cancer risk, incidence, morbidity, and mortality and enhance quality of life in cancer survivors through an orderly sequence from research on interventions and their impact in defined populations to the broad, systematic application of the research results through dissemination and diffusion strategies. Primary emphasis is on the inclusion of cancer prevention and control intervention(s) in any proposed study. Cancer Prevention and Cancer Control research studies are classified into one of five phases: (1) Hypothesis development; (2) methods development and testing; (3) controlled intervention trials to establish cause-and-effect relationships; (4) research in defined populations; and (5) demonstration and implementation studies. Primary interests are in research on cancer control interventions in Phases 2 through 5, and on cancer prevention research in all phases. Cancer Prevention and Control programs include those in the following areas: (1) cancer epidemiology; (2) cancer communications; (3) nutrition, diet, and physical activity; (4) screening and early detection in health care delivery; (5) biobehavioral mechanisms; (6) tobacco control; (7) health disparities research; (8) supportive care and survivorship; (9) health services and outcomes research; and (10) surveillance research. Cancer Control uses Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs to engage domestic small business concerns in federal research and development that has potential for commercialization. The goals of the SBIR & STTR Programs are to stimulate technological innovation, increase private-sector commercialization of federal research and development, increase small business participation in federally funded research and development, and foster participation by socially and economically disadvantaged small business concerns and women-owned small business concerns in technological innovation. The STTR Program requires the small business concern to formally collaborate with a research institution in Phase I and Phase II of the program.
Open opportunities
- Developing novel theory and methods for understanding the genetic architecture of complex human traits (R01 Clinical Trial Not Allowed)
- Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional)
- Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)
- Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)
- National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
- Developing novel theory and methods for understanding the genetic architecture of complex human traits (R21 Clinical Trial Not Allowed)
- Intervention Research to Improve Native American Health (R01 Clinical Trial Optional)
- Cancer Advancement through Partnerships in Research and Infrastructure (CAPRI) (U54 Clinical Trial Optional)
- Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed)
- Risk and Protective Factors of Family Health and Family Level Interventions (R01 Clinical Trial Optional)
- Screening, Brief Intervention and Referral to Treatment or Prevention (SBIRT/P) for alcohol, tobacco, and other drugs (ATOD) use and misuse in adult populations that experience health disparities (R01, Clinical Trial Required)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)
- Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional)
- Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
- Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
- Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
- Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)
- Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)
- Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)
- Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
Rules from the program listing
Who can apply
The awardee will be a university, college, hospital, public agency, nonprofit research institution or for-profit organization that submits an application and receives a grant or cooperative agreement for support of research by a named principal investigator. SBIR grants can be awarded only to domestic small businesses (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed, and have no more than 500 employees). Primary employment (more than one- half time) of the principal investigator must be with the small business at the time of award and for the duration of the project period. In both Phase I and Phase II, the research must be performed in the U.S. and its possessions. To be eligible for funding, a grant application must be approved for scientific merit, technical merit, and program relevance by a scientific review group and a national advisory council. STTR grants can be awarded only to domestic small business concern (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed and have no more than 500 employees) which "partner" with a research institution in cooperative research and development. At least 40 percent of the project is to be performed by the small business concern and at least 30 percent by the research institution.
What the money can and cannot pay for
Grants and cooperative agreements may be made to eligible institutions for the support of cancer research projects. The grants and cooperative agreements may be used for personnel, consultant costs, equipment, supplies, travel, patient costs, animals, alterations and renovations, miscellaneous items, and indirect costs. Restrictions are imposed against the use of funds for entertainment, foreign travel (unless specifically authorized), office equipment, and other items not normally necessary for the effective prosecution of such research. SBIR Phase I grants (of approximately 6-months' duration) are to establish the technical merit, feasibility and commercial potential of a proposed research effort and to determine the quality of performance of the awardee. Phase II grants are for the continuation of the research initiated in Phase I, and are likely to result in commercial products or processes. Only SBIR Phase I awardees are eligible to receive Phase II support. STTR Phase I grants (normally of 1-year duration) are to determine the scientific, technical, and commercial merit and feasibility of the proposed cooperative effort that has potential for commercial application. Phase II funding is based on results of research initiated in Phase I, and the scientific and technical merit and commercial potential of the proposed Phase II project. Only STTR Phase I awardees are eligible to receive Phase II support.
Matching requirements
This program has no statutory formula. Matching requirements are not applicable to this assistance listing. MOE requirements are not applicable to this assistance listing.
Funding history and past recipients
From fiscal 2021 to 2025, Cancer Control (93.399) awarded$814 million across 113 grant awards, an average of $7.2 million per award.
Who usually wins
Nonprofits received 64% of the money, colleges and universities 26% and state and local governments 7.2%.
| Recipient type | Awards | Amount | Share |
|---|---|---|---|
| Nonprofits | 47 | $524 million | 64% |
| Colleges and universities | 56 | $213 million | 26% |
| State and local governments | 4 | $59.0 million | 7.2% |
| Other | 5 | $11.9 million | 1.5% |
| Businesses | 1 | $5.9 million | 0.7% |
By state
36 states have a page for this program: those that received at least $1 million or 10 awards.
| State | Awards | Amount |
|---|---|---|
| Pennsylvania | 5 | $157 million |
| Illinois | 7 | $95.2 million |
| New York | 10 | $62.0 million |
| California | 9 | $54.0 million |
| Wisconsin | 6 | $44.3 million |
| Michigan | 7 | $41.1 million |
| Washington | 8 | $40.9 million |
| North Carolina | 5 | $39.5 million |
| Oregon | 2 | $34.4 million |
| South Carolina | 3 | $27.1 million |
| Minnesota | 2 | $25.5 million |
| Texas | 4 | $18.5 million |
| Georgia | 4 | $17.7 million |
| Louisiana | 1 | $13.1 million |
| Delaware | 3 | $12.7 million |
| Colorado | 4 | $11.4 million |
| Virginia | 3 | $10.8 million |
| Ohio | 3 | $9.5 million |
| Kansas | 1 | $8.6 million |
| New Mexico | 1 | $8.1 million |
| Missouri | 3 | $7.8 million |
| Arizona | 1 | $7.6 million |
| Nevada | 1 | $7.3 million |
| Hawaii | 1 | $6.8 million |
| Iowa | 1 | $6.6 million |
| Tennessee | 1 | $6.4 million |
| Maine | 1 | $5.1 million |
| North Dakota | 1 | $5.0 million |
| Puerto Rico | 1 | $4.9 million |
| Montana | 1 | $4.5 million |
| New Jersey | 1 | $4.1 million |
| District of Columbia | 1 | $3.7 million |
| Florida | 1 | $3.5 million |
| Massachusetts | 3 | $2.3 million |
| Oklahoma | 1 | $1.6 million |
| Maryland | 1 | $1.4 million |
| Idaho | 1 | $280,294 |